Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 2:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 63 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Calcipotriene Clear all
Completed Phase 4 Interventional

Enstilar in Combination With Biologic Agents

NCT03080545
View directory record Official record
Conditions
Psoriasis
Interventions
Enstilar 0.005%-0.064% Topical Foam
Drug
Lead sponsor
Psoriasis Treatment Center of Central New Jersey
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
East Windsor, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 3, 2018 · Synced Oct 19, 2026, 2:26 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial Evaluating Efficacy and Safety of MC2-01 Cream

NCT03308799
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
MC2-01 cream, Cal/BDP combination, Cream vehicle
Drug
Lead sponsor
MC2 Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
794 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Detroit, Michigan • Fridley, Minnesota • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Oct 19, 2026, 2:26 AM EDT
Terminated Early Phase 1 Interventional Results available

Molecular Effects of Topical Calcipotriene on Morphea

NCT02411643
View directory record Official record
Conditions
Morphea, Localized Scleroderma
Interventions
topical calcipotriene 0.005% ointment
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Oct 19, 2026, 2:26 AM EDT
Completed Phase 2 Interventional Results available

Development of Vitamin D as a Therapy for Breast Cancer - Phase 2

NCT00656019
View directory record Official record
Conditions
Breast Cancer
Interventions
Vitamin D
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 2, 2017 · Synced Oct 19, 2026, 2:26 AM EDT
Not yet recruiting Phase 4 Interventional

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

NCT07352566
View directory record Official record
Conditions
Psoriasis, Atopic Dermatitis
Interventions
In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil, Calcipotriene, Tapinarof, Crisaborole, Tacrolimus, Adalimumab, Etanercept, Certolizumab, Infliximab, Secukinumab, Ixekizumab, Apremilast, Risankizumab, Ustekinumab, Hydroxychloroquine, Methotrexate, Mycophenolate, Azathioprine, Chloroquine, Cyclosporine, Tofacitinib, Deucravacitinib, Dupilumab, Tralokinumab, Guselkumab, Tildrakizumab, Baractinib, Abrocitinib, Upadacitinib, Lebrikizumab, Nemolizumab, Ruxolitinib, Bimekizumab, Roflumilast
Device · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 19, 2026, 2:26 AM EDT
Completed Phase 2 Interventional Results available

Effect of Calcipotriol Plus Hydrocortisone Ointment on the Adrenal Hormone Balance and Calcium Metabolism in Patients With Psoriasis Vulgaris on the Face and Skin Folds

NCT00704262
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
Calcipotriol plus hydrocortisone (LEO 80190)
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • Ormond Beach, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 19, 2026, 2:26 AM EDT
Completed Phase 4 Interventional

Combination of Sotyktu and Enstilar for Plaque Psoriasis

NCT06329258
View directory record Official record
Conditions
Psoriasis
Interventions
Enstilar, Deucravacitinib
Drug
Lead sponsor
Psoriasis Treatment Center of Central New Jersey
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
East Windsor, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Oct 19, 2026, 2:26 AM EDT
Completed Phase 1 Interventional

Evaluate Safety and Tolerability of Calcipotriene Foam 0.005% in Pediatric Subjects With Mild/Moderate Plaque Psoriasis

NCT01582932
View directory record Official record
Conditions
Psoriasis
Interventions
Calcipotriene 0.005% Foam
Drug
Lead sponsor
Mayne Pharma International Pty Ltd
Industry
Eligibility
2 Years to 11 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
36
States / cities
Birmingham, Alabama • Rogers, Arkansas • Encino, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Oct 19, 2026, 2:26 AM EDT
Recruiting Phase 2Phase 3 Interventional

5-Fluorouracil and Calcipotriene for Treatment of Low Grade Skin Cancer

NCT05381597
View directory record Official record
Conditions
Superficial Basal Cell Carcinoma, Squamous Cell Carcinoma in Situ
Interventions
Combination cream of 5-fluorouracil and calcipotriene, 5-fluorouracil cream
Drug
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 19, 2026, 2:26 AM EDT
Completed Phase 3 Interventional Results available

LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris

NCT01866163
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
LEO 90100, Vehicle
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 19, 2026, 2:26 AM EDT
Completed Phase 4 Interventional Results available

A Study Evaluating the Efficacy and Tolerability of Enstilar Foam in Patients With Nail Psoriasis

NCT04227288
View directory record Official record
Conditions
Nail Psoriasis
Interventions
Enstilar Foam
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 17, 2025 · Synced Oct 19, 2026, 2:26 AM EDT
Completed Phase 1 Interventional

Trial to Assess the Potency of SOR007 Ointment in a Psoriasis Plaque Test

NCT03004339
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
SOR007 Ointment 2.0%, SOR007 Ointment 1.0%, SOR007 Ointment 0.3%, SOR007 Ointment 0.15%, SOR007 Ointment Placebo, Taclonex® Ointment
Drug
Lead sponsor
DFB Soria, LLC
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Austin, Texas • College Station, Texas
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 19, 2026, 2:26 AM EDT
Completed Phase 2 Interventional Results available

A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream

NCT03462927
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
MC2-01 Cream, CAL/BDP combination
Drug
Lead sponsor
MC2 Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Sweetwater, Florida
Source: ClinicalTrials.gov public record
Updated Dec 24, 2019 · Synced Oct 19, 2026, 2:26 AM EDT
Recruiting Phase 4 Interventional

Taltz in Combination With Enstilar for Psoriasis

NCT04372277
View directory record Official record
Conditions
Psoriasis
Interventions
Enstilar
Drug
Lead sponsor
Psoriasis Treatment Center of Central New Jersey
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
East Windsor, New Jersey
Source: ClinicalTrials.gov public record
Updated May 4, 2020 · Synced Oct 19, 2026, 2:26 AM EDT
Completed Phase 4 Interventional Results available

Enstilar® Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color

NCT03506477
View directory record Official record
Conditions
Plaque Psoriasis, Psoriasis
Interventions
Enstilar® foam, Vehicle foam
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Oct 19, 2026, 2:26 AM EDT
Completed Not applicable Interventional

Topical Vitamin D in Acute Graft Versus Host Disease of the Skin

NCT03093805
View directory record Official record
Conditions
Graft Vs Host Disease
Interventions
Calcipotriene
Dietary Supplement
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
3 Months to 35 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Oct 19, 2026, 2:26 AM EDT
Withdrawn Phase 2 Interventional

Immunotherapy Before Transplantation for Skin Cancer Prevention in Organ Transplant Recipients

NCT04329221
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma, Actinic Keratoses, Skin Cancer, Organ Transplant Recipients, Immunotherapy
Interventions
Calcipotriol Only Product in Cutaneous Dose Form, Vaseline, Topical 5FU
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Oct 19, 2026, 2:26 AM EDT
Recruiting Phase 4 Interventional

Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis

NCT03827876
View directory record Official record
Conditions
Psoriasis
Interventions
Enstilar 0.005%-0.064% Topical Foam
Drug
Lead sponsor
Psoriasis Treatment Center of Central New Jersey
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
East Windsor, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Oct 19, 2026, 2:26 AM EDT
Completed Phase 3 Interventional Results available

Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis One of Two Phase 3 Studies

NCT00688519
View directory record Official record
Conditions
Psoriasis
Interventions
U0267, Vehicle
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
12 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
13
States / cities
San Diego, California • Denver, Colorado • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2017 · Synced Oct 19, 2026, 2:26 AM EDT
Recruiting Phase 3 Interventional

A Pilot Clinical Trial Comparing Topical Fluorouracil to Fluorouracil Plus Calcipotriene Field Treatments in Patients With Multiple Actinic Keratoses

NCT06851507
View directory record Official record
Conditions
Multiple Actinic Keratoses
Interventions
Fluorouracil 5-FU, Fluorouracil/Calcipotriene
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 19, 2026, 2:26 AM EDT
Withdrawn Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of P-3073 Nail Solution in the Treatment of Mild to Moderate Psoriatic Fingernail/s

NCT03079973
View directory record Official record
Conditions
Nail Psoriasis
Interventions
P-3073 (calcipotriene 0.005%), Vehicle of P-3073
Drug
Lead sponsor
Polichem S.A.
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
58
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2018 · Synced Oct 19, 2026, 2:26 AM EDT
Completed Phase 2 Interventional

Study of Dose-Effect of COL-121 Ointment in Patients With Plaque-Type Psoriasis

NCT00625326
View directory record Official record
Conditions
Plaque-type Psoriasis
Interventions
COL-121, 50 µg/g Calcipotriene Ointment, Placebo
Drug
Lead sponsor
Deltanoid Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
20
States / cities
Fremont, California • Los Angeles, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2011 · Synced Oct 19, 2026, 2:26 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis).

NCT03731091
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
Calcipotriene/ betamethasone dipropionate topical foam, 0.005%/0.064%, Enstilar® foam (LEO Pharma Inc.), Placebo of Calcipotriene/ betamethasone dipropionate topical foam
Drug · Other
Lead sponsor
Glenmark Pharmaceuticals Ltd. India
Industry
Eligibility
18 Years and older
Enrollment
494 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
30
States / cities
Encinitas, California • Fountain Valley, California • San Diego, California + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Oct 19, 2026, 2:26 AM EDT
Completed Phase 4 Interventional Results available

Olux E Foam and Sorilux Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis

NCT01745133
View directory record Official record
Conditions
Psoriasis
Interventions
vehicle foam, calcipotriene, calcipotriene + clobetasol propionate
Drug
Lead sponsor
Leon Kircik, M.D.
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 17, 2016 · Synced Oct 19, 2026, 2:26 AM EDT